|Articles|September 1, 2010
Asia-Pac Grows With China Focus
The status of the CRO industry and doing business in the most recently emerged of the Asia-Pac regions.
Advertisement
A review of the press releases being issued by companies in the clinical trials space for the first half of the year, a clear trend toward Asia—and specifically toward China—is noticeable. While India gained ground in the Asia Pacific region for years and has moved away from emerging to established, and Japan is clearly a different and entrenched Asian market, China continues its emerging status with an uptick in activity.
IMAGE SOURCE/IMAGE SOURCE/GETTY IMAGES/CLINICALTRIALS.GOV
Specifically, those companies and their activities in China include and are not limited to:
- Parexel announced two new locations in Chengdu and Guangzhou, China. The CRO already has 17 other locations in Asia-Pac.
- CRO Chiltern announced new offices in Australia and Singapore, building upon an existing operation in India.
- i3 acquired ChinaGate, a CRO based in Shanghai, to capitalize on its knowledge of the Chinese regulatory authority, the SFDA.